The objective of this study was to investigate the correlation between circulating tumor DNA (ctDNA) KRAS G12C–mutation dynamic variations and treatment outcomes in patients with advanced non‐small cell lung cancer (NSCLC) receiving sotorasib therapy in a real‐world setting. The gene discussed is KRAS; the disease is neoplasm.